• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home StudyGraphics

#VisualAbstract: Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease

byStudy Graphics | C.WuandConstance Wu
September 6, 2020
in StudyGraphics
Reading Time: 2 mins read
#VisualAbstract: Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease
Share on FacebookShare on Twitter

1. In this case-control study of patients of European ancestry with inflammatory bowel disease (IBD), variants in NUDT15 were associated with an increased risk of thiopurine-induced myelosuppression (TIM).

2. There were no sex-based differences in these genetic variants nor were there any differences based on IBD type.

Evidence Rating Level: 2 (Good)

Study Rundown: Thiopurine-induced myelosuppression (TIM) is an adverse drug reaction that occurs in approximately ten percent of patients who receive thiopurines for the management of inflammatory bowel disease (IBD). Currently, the FDA recommends genetic screening for the thiopurine S-methyltransferase (TPMT) gene prior to the initiation of thiopurine-based therapy. In this case-control study, IBD patients of European ancestry that had both the TPMT and the nudix hydrolase 15 (NUDT15) genes had an increased likelihood for developing TIM. For patients with the TPMT genetic variant, they were three times as likely to develop TIM while those with the NUDT15 genetic variant were thirty-eight times as likely to develop TIM. When patients had both genetic variants, they were significantly more likely to develop neutropenia, be hospitalized, and to have received granulocyte-colony stimulating factor rescue therapy. There were no sex-based differences in these genetic variants nor were there any differences based on IBD type.

While this study highlights some important applications of precision medicine, its conclusions are currently limited to patients of European ancestry. In order to more broadly apply these findings, these genetic variants should be studied in additional patient populations in order to increase the generalizability of these findings.

Click to read the study in JAMA

RELATED REPORTS

The incidence of ocular manifestations is higher in patients with Crohn’s disease compared to ulcerative colitis

2 Minute Medicine Rewind October 20, 2025

Use of risankizumab is effective in adult Crohn’s disease

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: IBDthiopurine-induced myelosuppression (TIM)
Previous Post

Study does not support use of low-dose aspirin after prostate cancer diagnosis

Next Post

#VisualAbstract: Duration of Initial Empirical Antibiotic Therapy and Outcomes in Very Low Birth Weight Infants

RelatedReports

Elective colectomy associated with improved survival in ulcerative colitis
Chronic Disease

The incidence of ocular manifestations is higher in patients with Crohn’s disease compared to ulcerative colitis

January 13, 2026
Using HEART score to risk stratify patients with chest pain is safe but underutilized in the ED
Weekly Rewinds

2 Minute Medicine Rewind October 20, 2025

October 20, 2025
Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease
Chronic Disease

Use of risankizumab is effective in adult Crohn’s disease

January 13, 2026
Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease
Chronic Disease

Ustekinumab may be superior to Vedolizumab for the treatment of Crohn’s disease

August 8, 2025
Next Post
#VisualAbstract: Duration of Initial Empirical Antibiotic Therapy and Outcomes in Very Low Birth Weight Infants

#VisualAbstract: Duration of Initial Empirical Antibiotic Therapy and Outcomes in Very Low Birth Weight Infants

Postextubation administration of high-flow oxygen leads to reduced reintubation and respiratory failure

The PreVent trial: bag-mask ventilation decreases hypoxia in patients undergoing tracheal intubation

Increasing C-section room temperature linked to reduced neonatal, maternal hypothermia

Maternal gratitude linked to improved medical staff functioning

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Transanastomotic tubes not linked to anastomotic stricture after esophageal atresia repair
  • Artificial intelligence (AI) chatbot reduced depression, anxiety, and eating disorder risk symptoms
  • Real-time AI guidance enters live brain tumor surgery
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.